Atypical haemolytic uraemic syndrome and mutations in complement regulator genes
- 28 September 2005
- journal article
- review article
- Published by Springer Nature in Springer Seminars in Immunopathology
- Vol. 27 (3) , 359-374
Abstract
Haemolytic uraemic syndrome (HUS) is a thrombotic microangiopathy (TMA) disorder characterised by the association of haemolytic anaemia, thrombocytopenia and acute renal failure. Atypical forms (non-related to shigatoxin) may be familial or sporadic, with frequent recurrences and most of them lead to end stage renal failure. During the last years, different groups have demonstrated genetic predisposition of atypical HUS involving complement components factor H (FH), CD46 [or membrane co-factor protein (MCP)] and factor I. These three proteins are involved in the regulation of the alternative pathway of the complement system. Several series have reported mutations in the FH gene (called HF1) in between 10 and 22% of atypical HUS patients. At this time, four pedigrees corresponding to 13 cases have been reported with an MCP mutation and four cases with a sporadic disease presented factor I mutation. Whereas FH mutations were reported in both familial and sporadic forms of HUS, CD46 mutations were restricted to familial HUS, and factor I mutations were only observed in cases of sporadic HUS. We speculate that the penetrance of the disease may be variable regarding the identified susceptibility factors. Recently, the analysis of single nucleotide polymorphisms in both HF1 and MCP in three large cohorts of HUS patients identified significant association between atypical HUS and HF1 and MCP particular alleles. All these results, together with the finding of anti-FH antibodies in some atypical HUS patients, strongly suggest that an abnormality in the regulation of the alternative pathway participates in the patho-physiological mechanisms of atypical HUS. The recent progress made in the determination of susceptibility factors for atypical HUS has permitted the development of new diagnostic tests and may eventually lead to new specific treatments to block the pathological process.Keywords
This publication has 47 references indexed in Scilit:
- The development of atypical haemolytic-uraemic syndrome is influenced by susceptibility factors in factor H and membrane cofactor protein: evidence from two independent cohortsJournal of Medical Genetics, 2005
- CD46: expanding beyond complement regulationTrends in Immunology, 2004
- Challenges in the management of infantile factor H associated hemolytic uremic syndromePediatric Nephrology, 2004
- Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countriesJournal of Medical Genetics, 2003
- Molecular modelling of the C-terminal domains of factor H of human complement: a correlation between haemolytic uraemic syndrome and a predicted heparin binding siteJournal of Molecular Biology, 2002
- Factor H Mutations in Hemolytic Uremic Syndrome Cluster in Exons 18–20, a Domain Important for Host Cell RecognitionThe American Journal of Human Genetics, 2001
- Clustering of Missense Mutations in the C-Terminal Region of Factor H in Atypical Hemolytic Uremic SyndromeThe American Journal of Human Genetics, 2001
- Genetic studies into inherited and sporadic hemolytic uremic syndromeKidney International, 1998
- Enteropathogens associated with childhood diarrhea in ItalyThe Pediatric Infectious Disease Journal, 1996
- Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution.Journal of Experimental Medicine, 1977